MRK

NYSE · Pharmaceuticals

Merck & Co. Inc.

S&P 500 Dow Jones Mega-Cap Stocks Blue Chip Stocks Pharmaceutical Stocks Healthcare Stocks Best Dividend Stocks

$123.82

+1.56 (+1.28%)

As of Feb 24, 1:03 PM ET ·

Financial Highlights (FY 2026)

Revenue

64.24B

Net Income

18.04B

Gross Margin

81.5%

Profit Margin

28.1%

Rev Growth

+3.1%

D/E Ratio

0.80

Revenue & Net Income

Margin Trends

	FY 2026	FY 2025	FY 2024	FY 2023
Gross Margin	81.5%	81.5%	60.0%	60.0%
Operating Margin	32.6%	29.4%	19.9%	18.6%
Profit Margin	28.1%	26.7%	14.5%	15.3%

Income Statement

	FY 2026	FY 2025	FY 2024	FY 2023
Revenue	64.24B	62.30B	122.92B	97.21B
Gross Profit	52.36B	50.77B	73.70B	58.29B
Operating Income	20.97B	18.30B	24.40B	18.09B
Net Income	18.04B	15.74B	17.77B	14.84B
Gross Margin	81.5%	81.5%	60.0%	60.0%
Operating Margin	32.6%	29.4%	19.9%	18.6%
Profit Margin	28.1%	26.7%	14.5%	15.3%
Rev Growth	+3.1%	+3.1%	+3.7%	+0.8%

Balance Sheet

	FY 2026	FY 2025	FY 2024	FY 2023
Total Debt	66.99B	66.99B	126.52B	165.60B
Total Equity	83.60B	83.60B	163.18B	146.99B
D/E Ratio	0.80	0.80	0.78	1.13

Cash Flow

	FY 2026	FY 2025	FY 2024	FY 2023
EBITDA	21.47B	19.78B	40.31B	27.40B
Free Cash Flow	—	—	15.03B	9.18B